Rock Creek Pharmaceuticals Inc  

(Public, OTCMKTS:RCPIQ)   Watch this stock  
Find more results for NASDAQ:STSI
+0.00020 (16.67%)
Sep 20 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.00 - 0.00
52 week 0.00 - 0.02
Open 0.00
Vol / Avg. 217,716.00/190,235.00
Mkt cap 238,618.00
P/E     -
Div/yield     -
EPS -0.78
Shares 170.44M
Beta 1.53
Inst. own 0%
Sep 21, 2017
Q2 2017 Rock Creek Pharmaceuticals Inc Earnings Release - 4:00PM EDT - Add to calendar

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -87.05% -48.33%
Return on average equity - -
Employees 10 -
CDP Score - -


2040 Whitfield Avenue, Suite 300
United States - Map
+1-804-5271970 (Phone)
+1-302-6365454 (Fax)

Website links


Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. The Company's activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine. The Company has completed Phase I safety studies of its product candidate in Europe. In pre-clinical testing, anatabine demonstrates anti-inflammatory activity in a range of in vitro and in vivo assays.

Officers and directors

Michael John Mullan Ph.D. M.D. Chairman of the Board, Office of President, Chief Executive Officer
Age: 59
William L. McMahon Chief Financial Officer
Age: 64
Theodore Jenkins Secretary, Vice President - Corporate Strategy & Development
Lee M. Canaan Independent Director
Age: 59
Robert W. Scannell Independent Director
Age: 57